One of the main advantages of direct inhibitors is their specificity, which generally results in fewer side effects compared to traditional treatments. They can also be very effective in cancers that are driven by specific molecular abnormalities. However, there are some disadvantages. Cancer cells can develop resistance to these drugs over time, necessitating combination therapies or the development of next-generation inhibitors. Additionally, these treatments can be expensive, and their efficacy may be limited to cancers with specific mutations.
